The Grünenthal Group
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany.
Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation. Grünenthal is one of the last remaining five research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. These investments amounted to about 20 percent of revenues in 2014.
EFIC-Grünenthal Grant honours 7 young scientists for their groundbreaking pain research ideas
Pain is a common condition, which affects one in five adult citizens in Europe. They have persistent or chronic pain, a condition which affects the everyday lives of millions of people worldwide and which also poses a huge economic burden. Since 2004 the European Pain Federation EFIC® has cooperated with Grünenthal, to support up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects. The focus lies on novel ideas with potential for achieving major advances in the understanding of pain mechanisms and its treatment.
Grünenthal donates a total of 200,000€ as biennial grant; individual grants are valued at up to 40,000€ per project for a duration of up to two years.